Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $3.9 million.

  • Agios Pharmaceuticals' Other Non-Current Assets fell 310.65% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 310.65%. This contributed to the annual value of $4.7 million for FY2024, which is 1644.07% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Other Non-Current Assets of $3.9 million as of Q3 2025, which was down 310.65% from $3.9 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Other Non-Current Assets peaked at $4.7 million during Q4 2024, and registered a low of $2.9 million during Q2 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Other Non-Current Assets value was $4.0 million (recorded in 2022), while the average stood at $3.8 million.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Other Non-Current Assets showed a top increase of 11481.48% in 2021 and a maximum decrease of 9394.05% in 2021.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Other Non-Current Assets stood at $2.9 million in 2021, then soared by 36.41% to $4.0 million in 2022, then grew by 2.55% to $4.1 million in 2023, then rose by 16.44% to $4.7 million in 2024, then fell by 16.81% to $3.9 million in 2025.
  • Its Other Non-Current Assets stands at $3.9 million for Q3 2025, versus $3.9 million for Q2 2025 and $4.7 million for Q1 2025.